Tagged with oncology,

UCB UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan for regional expansion through partnerships. Given your patient centricity and UCB’s unique perspective, how would you assess the sectors approach…

cancer Eduardo Payet of INEN outlines the institution’s agenda for preventing advanced stages of cancer and plans to expand oncology services beyond Lima to more remote regions of Peru. What is your assessment of the state of cancer in Peru today? Peru is experiencing a demographic and epidemiological transition as a…

oncology Despite Peru’s sometimes-sluggish development when it comes to healthcare, the progression of cancer prevention and control in recent decades is tremendous. This is particularly important as the number of cancer cases increases by 50,000 annually in Peru. Communicable diseases like infectious diseases, which used to be a predominant cause of death…

biotech SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a cure for cancer’.   Could you please introduce yourself Dr. Moon, and tell us how you became involved with SillaJen? …

oncology In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its go-to-market strategy and has succeeded in positioning itself as a top player in women’s health and primary care, lead by…

development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations.    How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…

Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…